Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Warns Of Further Shortages Of Cerezyme, Fabrazyme

This article was originally published in The Pink Sheet Daily

Executive Summary

Fabrazyme may be unavailable in some regions from July through September, the company warned.

You may also be interested in...



Human Genetic Therapies Boosts Shire, Thanks To Replagal Growth

Genzyme's inability to provide Fabry disease patients with Fabrazyme has created an opening for Replagal, whose half-year sales are up 77 percent year-over-year.

Human Genetic Therapies Boosts Shire, Thanks To Replagal Growth

Genzyme's inability to provide Fabry disease patients with Fabrazyme has created an opening for Replagal, whose half-year sales are up 77 percent year-over-year.

Under Pressure: Sanofi's Strategy Will Be Tested By Generic Lovenox Approval

Ahead of the big pharma's earnings call July 29, Sanofi-Aventis is under renewed pressure with Momenta and partner Sandoz promising a swift launch of their newly approved generic version of Lovenox.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel